The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839

Material

Thursday 5 Nov642 filings read · 590 material

  • 8-KFiled 5 Nov 2026Biotech

    Celldex Therapeutics, Inc.CLDX

    8-K · Item 2.02 — Results of operations

    Celldex reported best-in-disease Phase 3 results for barzolvolimab in chronic spontaneous urticaria, meeting primary and key secondary endpoints with unprecedented complete response rates. BLA submission anticipated in 2027. Pipeline advancing across multiple indications.

    Gap Medium · 17 → High · 29

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Ironwood Pharmaceuticals IncIRWD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 42 → Balanced 53

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    NCR Voyix CorpVYX

    8-K · Item 2.01 — Acquisition or disposal of assets

    Recognition: Balanced 62 → Strong 65Value: Balanced 57 → Balanced 54Gap High · 29 → High · 26

    The shares became dearer on AIR's value read.

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Industrials

    iRhythm Holdings, Inc.IRTC

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 14.9% YoY to $221.6M; gross margin expanded 310bps to 74.2%. Adjusted EBITDA improved $29.6M to $51.2M. VitalConnect acquisition closed; FY2026 revenue and EBITDA margin guidance raised.

    Recognition: Balanced 61 → Balanced 55Gap High · 35 → Very high · 48

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026Semiconductors

    Diodes Inc /Del/DIOD

    8-K · Item 2.02 — Results of operations

    Diodes reported record Q3 2026 revenue of $532.6M (+35.8% YoY), gross margin expansion to 36.1% (+540 bps YoY), and non-GAAP EPS of $1.18 (+219% YoY). Q4 guidance projects ~$550M revenue (+40% YoY) with 37% gross margin.

    Gap Very high · 62 → Very high · 59

    The gap narrowed — attention is catching up.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Banks

    Hyperliquid Strategies IncPURR

    8-K · Item 2.02 — Results of operations

    HSI deployed $802M in Q1 FY2027, acquiring 9.1M HYPE tokens and repurchasing 2.7M PURR shares. Filed FCM application to bring regulated perpetual futures onshore. Raised $911M in equity capital. Reported $620.6M net income, primarily from unrealized HYPE gains.

    Recognition: Strong 73 → Strong 69

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Industrials

    Haemonetics CorpHAE

    Quarterly report (10-Q), period ending 26 Sep 2026

    Gap Low · 2 → Medium · 12

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Nexstar Media Group, Inc.NXST

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Balanced 54 → Strong 65Gap High · 29 → High · 36

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 5 Nov 2026Industrials

    Park Ohio Holdings CorpPKOH

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Balanced 48 → Watch 44Gap Low · 0 → Low · 6

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    PENN Entertainment, Inc.PENN

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Strong 79 → Strong 69Gap High · 25 → High · 32

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Industrials

    Patrick Industries IncPATK

    Quarterly report (10-Q), period ending 27 Sep 2026

    Value: Balanced 54 → Balanced 60

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Rigel Pharmaceuticals IncRIGL

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 60 → Balanced 57Gap High · 27 → High · 38

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    American Financial Group IncAFG

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 3 → Medium · 17

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Ani Pharmaceuticals IncANIP

    8-K · Items 1.01, 2.03, 8.01 — Material agreement

    Recognition: Balanced 51 → Balanced 48Value: Very strong 82 → Very strong 85Gap Medium · 16 → High · 29

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 5 Nov 2026All industries

    Brunswick CorpBC

    Quarterly report (10-Q), period ending 3 Oct 2026

    No notable change in AIR's read.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    Vse CorpVSEC

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 29 → Weak 24Gap Very high · 56 → Very high · 59

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Valhi Inc /De/VHI

    8-K · Item 2.02 — Results of operations

    Q3 2026 net income of $30.2M ($1.06/share) vs. Q3 2025 loss of $22.2M ($.78/share). YTD 2026 net income $54.5M ($1.91/share) vs. YTD 2025 loss of $4.4M ($.15/share). Chemicals segment drove gains via market share, pricing, and cost controls.

    Recognition: Weak 24 → Watch 27Value: Very strong 85 → Strong 73

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Haemonetics CorpHAE

    8-K · Item 2.02 — Results of operations

    HAE reported Q2 FY2027 revenue of $358M (+9.3% YoY), organic growth of 10%, and raised full-year guidance. Apheresis grew 12.6%, MedSurg 5.1%. Adjusted EPS $1.35 (+6.3%). Gross margin expanded 140 bps. Guidance raised to 8-11% reported revenue growth and 6-9% organic growth.

    Gap Low · 2 → Medium · 12

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Investors Title CoITIC

    8-K · Item 2.02 — Results of operations

    Q3 2026 net income declined 23% YoY to $9.4M ($4.97/share) despite 12.1% revenue growth. Higher claims provisions, investment losses, and operating expense growth (21.7%) offset premium revenue gains. YTD results improved 8.9%.

    Recognition: Balanced 54 → Balanced 51Value: Balanced 56 → Balanced 49

    Market attention has faded.

    The shares became dearer on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Industrials

    Lci IndustriesLCII

    8-K · Item 2.02 — Results of operations

    Q3 2026 net sales declined 4% YoY to $992M; net income fell 20% to $2.05 EPS. RV OEM sales dropped 17%. Adjusted metrics improved, but core GAAP results missed prior year despite margin expansion efforts.

    Gap High · 27 → Medium · 13

    The gap narrowed — attention is catching up.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Distribution Solutions Group, Inc.DSGR

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 10.7% YoY to $573.6M with 9.2% organic growth. Adjusted EBITDA margin improved 50bps to 9.9%. Net income rose 37.8% YoY. Company completed American Fasteners acquisition and closed GradeEight post-quarter. Pending $35/share merger with LKCM Headwater (81% premium to March 2026 price).

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Par Technology CorpPAR

    8-K · Item 2.02 — Results of operations

    PAR Technology reported Q3 2026 revenue of $137.1M (+15% YoY), ARR of $354.5M (+18.1% YoY), and improved profitability. Company raised full-year 2026 revenue and Adjusted EBITDA guidance. PAR Intelligence deployment tracking ahead of 50,000-site goal.

    Recognition: Balanced 52 → Balanced 56

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    Par Technology CorpPAR

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 52 → Balanced 56

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    MIDDLEBY CorpMIDD

    8-K · Item 2.02 — Results of operations

    Q3 2026 net sales reached record $653M (+7.7% YoY), exceeding guidance. Adjusted EBITDA grew 10% to $156M with margin expansion. Company raised FY2026 organic growth guidance to 7-8%. Brewing business closure on track.

    Value: Watch 36 → Watch 27Gap Very high · 56 → Very high · 60

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Astec Industries IncASTE

    8-K · Item 2.02 — Results of operations

    Q3 2026 net loss of $12.2M vs. prior-year loss of $4.2M. Sales flat at $352.4M (+0.7%). Full-year Adjusted EBITDA guidance cut from $160–175M to $140–150M due to macroeconomic uncertainty, order pauses, and inflationary pressures. Backlog grew 49.2% but margins compressed significantly.

    Gap Medium · 21 → Low · 2

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 5 Nov 2026Industrials

    Lci IndustriesLCII

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 27 → Medium · 13

    The gap narrowed — attention is catching up.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 5 Nov 2026All industries

    Gibraltar Industries, Inc.ROCK

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 43 → Watch 39Value: Watch 27 → Watch 40Gap Very high · 75 → Very high · 70

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 5 Nov 2026All industries

    Weis Markets IncWMK

    Quarterly report (10-Q), period ending 26 Sep 2026

    Recognition: Watch 38 → Watch 41

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Insight Enterprises IncNSIT

    8-K · Item 2.02 — Results of operations

    Insight Enterprises reported Q3 2026 results with 22% net sales growth, 20% gross profit growth, and 34% adjusted EPS growth. Company raised full-year 2026 guidance for gross profit growth (12.5–14.0%) and adjusted EPS ($13.55–$13.75, ~27% growth).

    Recognition: Strong 72 → Strong 69Value: Watch 35 → Watch 26Gap Medium · 15 → Medium · 23

    Market attention has faded.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Acacia Research CorpACTG

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 4 → Low · 0

    The gap closed as the filings read less positively.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Fulgent Genetics, Inc.FLGT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $90.4M grew 8% YoY, but GAAP loss of $13.2M and Non-GAAP loss of $2.4M indicate profitability challenges. Company improved full-year guidance on cost discipline, but gross margin declined and collection issues persist.

    Recognition: Balanced 46 → Balanced 54Gap High · 35 → Medium · 20

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    Aci Worldwide, Inc.ACIW

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $427M with net income of $33M and adjusted EBITDA of $98M. Company raised full-year 2026 adjusted EBITDA guidance to $550-565M (from $545-560M). Strong ARR bookings up 86% YTD, successful ACI Connetic go-live with two additional wins, and Cranium Ventures acquisition announced.

    Gap Low · 5 → Medium · 12

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026Software / SaaS

    Aci Worldwide, Inc.ACIW

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 5 → Medium · 12

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Precigen, Inc.PGEN

    8-K · Item 2.02 — Results of operations

    PAPZIMEOS net revenue grew 37% QoQ to $72.9M in Q3 2026. Company achieved positive operating cash flow ($11.9M) one quarter ahead of guidance. Net income was $35.8M ($0.08 diluted EPS). FDA granted Platform Technology Designation to AdenoVerse platform.

    Value: Watch 41 → Balanced 54Gap Low · 0 → Low · 6

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Novavax IncNVAX

    8-K · Item 2.02 — Results of operations

    Novavax raised full-year 2026 revenue guidance by $145M to $400M midpoint, earned $125M Sanofi milestone for Phase 3 CIC trial initiation in Europe, and improved expense guidance. Q3 revenue flat YoY at $68M; net loss improved to $31M from $202M.

    Value: Watch 35 → Watch 32Gap Low · 0 → Low · 7

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026Software / SaaS

    Open Text CorpOTEX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Strong 79 → Very strong 83Gap Low · 7 → High · 30

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Ani Pharmaceuticals IncANIP

    8-K · Item 2.02 — Results of operations

    ANI Pharmaceuticals reported Q3 2026 revenues of $290.8M (+27.6% YoY), with Cortrophin Gel up 36.1% to $138.7M. Company raised full-year EBITDA and EPS guidance and announced acquisition of Egetis Therapeutics for ~$560M to expand rare disease portfolio.

    Recognition: Balanced 51 → Balanced 48Value: Very strong 82 → Very strong 85Gap Medium · 16 → High · 29

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Cra International, Inc.CRAI

    8-K · Item 2.02 — Results of operations

    CRA reported Q3 2026 revenue of $214.9M (+15.6% YoY), record quarterly net income of $13.9M (+21.2% YoY), and EPS of $2.20 (+27.2% YoY). Company raised full-year revenue guidance to $830–840M and narrowed EBITDA margin to 12.2–12.8%. Dividend increased 17.5%.

    Gap Low · 0 → Medium · 13

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    Cra International, Inc.CRAI

    Quarterly report (10-Q), period ending 3 Oct 2026

    Gap Low · 0 → Medium · 13

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026All industries

    Northern Oil & Gas, Inc.NOG

    8-K · Item 2.02 — Results of operations

    NOG reported record Q3 2026 production (156,239 Boe/day, +19% YoY), record Adjusted EBITDA ($444.5M), and strong free cash flow ($148.6M). Company raised full-year production guidance to 147,000–150,000 Boe/day while maintaining capex budget, reduced debt by $100M+, and achieved sub-1.5x net leverage.

    Gap Very high · 70 → Very high · 74

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Banks

    Walker & Dunlop, Inc.WD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 72 → Very high · 65

    The gap narrowed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 5 Nov 2026All industries

    Matson, Inc.MATX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Strong 74 → Strong 71Gap Low · 7 → Medium · 15

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    FS KKR Capital CorpFSK

    8-K · Item 2.02 — Results of operations

    Recognition: Watch 28 → Watch 31

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Banks

    Resolute Holdings Management, Inc.RHLD

    8-K · Items 2.02, 8.01 — Results of operations

    Q3 2026: Non-GAAP Fee-Related EPS surged to $0.69 vs. $0.13 YoY, driven by Husky Holdings management agreement (Jan 2026) and organic CompoSecure growth. Board authorized $100M share repurchase program.

    Recognition: Watch 26 → Watch 37

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Ironwood Pharmaceuticals IncIRWD

    8-K · Item 2.02 — Results of operations

    Ironwood raised 2026 financial guidance driven by strong Q3 LINZESS U.S. sales ($325M, +3.2% YoY). Full-year LINZESS guidance raised to $1.20–$1.25B (>35% YoY growth); total revenue to $485–$510M; adjusted EBITDA to >$350M. Q3 GAAP net income $59.8M; adjusted EBITDA $97.9M (record).

    Recognition: Watch 42 → Balanced 53

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    CION Investment CorpCION

    8-K · Item 2.02 — Results of operations

    CION successfully completed deleveraging strategy, reducing debt from $1.17B to $897M and achieving 1.30x net debt-to-equity ratio below target. Q3 2026 net investment income was $0.25/share; earnings were $(0.07)/share due to realized losses from restructuring and asset sales to new SLFP joint venture.

    Gap Very high · 46 → Very high · 57

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    AGNT, Inc.AGNT

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 6% YoY to $1.4B, but net loss of $4.3M vs. prior-year profit of $3.5M. Adjusted EBITDA declined 3%. Agent NPS fell from 75 to 67. Q4 guidance projects Adjusted EBITDA of $(7)M to $0M.

    Value: Very strong 81 → Very strong 85Gap Low · 6 → Low · 0

    The shares became cheaper on AIR's value read.

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 5 Nov 2026All industries

    AGNT, Inc.AGNT

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Very strong 81 → Very strong 85Gap Low · 6 → Low · 0

    The shares became cheaper on AIR's value read.

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Willdan Group, Inc.WLDN

    8-K · Items 1.01, 2.01, 2.03 — Material agreement

    Willdan completed acquisition of Mantis Innovation for $285M, adding building controls, energy efficiency, and facility management capabilities. Funded via $250M new term loan and $35M revolving credit. Closes on HSR approval.

    News flow: Balanced 51 → Balanced 57Recognition: Balanced 46 → Watch 43Gap High · 27 → Very high · 93

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Westrock Coffee CoWEST

    8-K · Item 2.02 — Results of operations

    Q3 2026 net loss improved to $10.0M from $19.1M YoY. Consolidated Adjusted EBITDA grew 14.0% to $26.4M, marking sixth consecutive quarter of YoY growth. Company reaffirmed 2026 guidance and provided preliminary 2027 Adjusted EBITDA guidance of ~$130M, representing significant growth.

    Recognition: Balanced 48 → Watch 39Gap Very high · 81 → Very high · 88

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Protagonist Therapeutics, IncPTGX

    8-K · Item 2.02 — Results of operations

    FDA approved MIMRYLO (rusfertide) for polycythemia vera, triggering $275M in payments to Protagonist. Q3 2026 net income $220M vs. prior-year loss of $39M. Strong cash position of $835M supports pipeline advancement and $300M share repurchase program.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Valhi Inc /De/VHI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Weak 24 → Watch 27Value: Very strong 85 → Strong 73

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Clean Energy Fuels Corp.CLNE

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 38 → Watch 43Gap Low · 0 → Medium · 13

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Cryoport, Inc.CYRX

    8-K · Item 2.02 — Results of operations

    Cryoport reported Q3 2026 revenue of $50.2M (+14% YoY), with commercial CGT revenue up 20%. Company raised full-year 2026 guidance to $197–199M. Achieved positive adjusted EBITDA of $1.1M and supports record 788 clinical trials and 23 approved therapies.

    Recognition: Balanced 60 → Strong 66

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 5 Nov 2026Banks

    Mid Penn Bancorp IncMPB

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 65 → Very high · 62

    The gap narrowed — attention is catching up.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Cryoport, Inc.CYRX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 60 → Strong 66

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Westrock Coffee CoWEST

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 48 → Watch 39Gap Very high · 81 → Very high · 88

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Corvus Pharmaceuticals, Inc.CRVS

    8-K · Item 2.02 — Results of operations

    Corvus reports Q3 2026 results with $202.9M cash (runway to Q2 2028), multiple soquelitinib trials on track including Phase 3 PTCL, Phase 2 atopic dermatitis, and new Phase 1b hidradenitis suppurativa. Angel Pharma completed first cohort enrollment with data expected March 2027.

    Gap Low · 0 → Medium · 16

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Reinsurance Group Of America IncRGA

    8-K · Item 2.02 — Results of operations

    RGA reported Q3 2026 net income of $6.92 per diluted share (vs. $3.81 prior year) and adjusted operating income of $8.49 per diluted share (vs. $4.66 prior year). Strong investment performance, favorable claims experience, and robust premium growth across regions drove results.

    Value: Balanced 52 → Balanced 48

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    Aspen Aerogels IncASPN

    8-K · Items 2.02, 5.02 — Results of operations

    Q3 2026 revenue of $85.2M (+71% QoQ, above guidance); Adjusted EBITDA $19.8M (above high end); entered data center infrastructure market; secured 2027 project; record EU OEM revenue.

    Gap Low · 0 → Medium · 21

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    Macerich CoMAC

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Strong 68 → Balanced 63Gap Low · 2 → Medium · 11

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Insight Enterprises IncNSIT

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Strong 72 → Strong 69Value: Watch 35 → Watch 26Gap Medium · 15 → Medium · 23

    Market attention has faded.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Halozyme Therapeutics, Inc.HALO

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 39% YoY to $493M; royalty revenue up 44% to $341M. Company raised full-year 2026 guidance across all metrics. Three ENHANZE programs advanced to Phase 1; expanded partnerships with argenx, Incyte, and J&J. Dutch court granted injunction against Merck's Keytruda Qlex in eight European markets.

    Recognition: Very strong 86 → Very strong 80Value: Watch 38 → Balanced 61Gap Low · 3 → Medium · 10

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Barrett Business Services IncBBSI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 30 → Watch 26Gap Low · 7 → Low · 0

    Market attention has faded.

    The gap closed as the filings read less positively.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Acadia Pharmaceuticals IncACAD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Strong 74 → Very strong 83

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Comstock Resources IncCRK

    8-K · Item 2.02 — Results of operations

    Q3 2026 production grew 9% YoY; $1.65B SOCAR divestiture announced to strengthen balance sheet; bank facility extended to 2028/2031; operating cash flow $208M; adjusted EBITDAX $266M.

    Recognition: Watch 27 → Watch 33

    More of the market is starting to notice.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    LifeStance Health Group, Inc.LFST

    8-K · Item 2.02 — Results of operations

    LifeStance reported Q3 2026 revenue of $455.9M (+25% YoY), net income of $22.4M vs. $1.1M prior year, and Adjusted EBITDA of $68.4M (+70% YoY). Company raised full-year 2026 guidance across all metrics: revenue to $1.741–$1.761B, Center Margin to $599–$613M, and Adjusted EBITDA to $242–$250M.

    Gap Low · 6 → Medium · 12

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 5 Nov 2026All industries

    Yum China Holdings, Inc.YUMC

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 40 → Watch 44Value: Balanced 58 → Balanced 53Gap Very high · 75 → Very high · 84

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026All industries

    Mativ Holdings, Inc.MATV

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Strong 78 → Strong 73Gap Low · 4 → Low · 0

    The shares became dearer on AIR's value read.

    The gap closed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Novavax IncNVAX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 35 → Watch 32Gap Low · 0 → Low · 7

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    First Advantage CorpFA

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 13.8% YoY to $465.8M with 29.3% Adjusted EBITDA margin. Net income surged to $20.5M (vs. $2.6M prior year). Company raised full-year 2026 guidance across all metrics and announced Data Diver Technologies acquisition to enhance AI-driven screening capabilities.

    Gap High · 25 → High · 35

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 5 Nov 2026All industries

    MidCap Financial Investment CorpMFIC

    8-K · Item 2.02 — Results of operations

    MFIC announced Q3 2026 results showing net investment income decline to $0.34/share (vs. $0.40 prior quarter), NAV per share fell 3.8% to $12.86, and net realized losses of $44M. Company agreed to be acquired by Ares Capital at $10.88/share.

    Gap Medium · 23 → Low · 4

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Graham CorpGHM

    8-K · Item 2.02 — Results of operations

    Graham Corp reported Q2 FY27 results with 6% revenue growth to $69.8M, gross margin expansion of 650bps to 28.2%, and 39% EPS growth to $0.39. Record backlog of $561.3M (7th consecutive quarter) and strong cash generation of $46.7M. Reaffirmed full-year guidance.

    Recognition: Balanced 48 → Balanced 52Value: Weak 18 → Watch 25Gap Very high · 49 → Very high · 54

    More of the market is starting to notice.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 5 Nov 2026All industries

    Geo Group IncGEO

    8-K · Item 2.02 — Results of operations

    GEO reported Q3 2026 revenues of $761.1M (+12% YoY), adjusted net income of $51.8M (+48% YoY), and adjusted EBITDA of $145.3M (+21% YoY). Full-year guidance raised across all metrics. Major wins include $500M in new/expanded contracts YTD and $950M Adelanto facility sale.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Amylyx Pharmaceuticals, Inc.AMLX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 35 → High · 43

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 5 Nov 2026Software / SaaS

    TripAdvisor, Inc.TRIP

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue declined 11% YoY to $436.4M. GAAP net loss of $316.9M driven by $369.5M goodwill impairment in Hotels segment. Adjusted EBITDA fell 34% to $71.1M. Company initiated restructuring targeting $40M annualized savings.

    Recognition: Watch 44 → Watch 41Value: Strong 73 → Very strong 87

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 5 Nov 2026All industries

    Wendy's CoWEN

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show significant deterioration: global systemwide sales down 5.9%, U.S. same-restaurant sales down 5.7%, net income down 65.9% YoY, adjusted EBITDA down 17.8%. Company launched Dave's Way strategy and signed LOI to acquire 163 Meritage restaurants, but near-term performance remains weak.

    News flow: Balanced 49 → Watch 44Recognition: Watch 42 → Balanced 46

    The filings read less positively.

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 5 Nov 2026Biotech

    Climb Bio, Inc.CLYM

    8-K · Item 2.02 — Results of operations

    Climb Bio reported Q3 2026 results with positive clinical data across two lead programs. CLYM116 Phase 1 showed sustained >90% APRIL suppression supporting Q12W dosing; NAVIGATE-2 Phase 2 initiated. Budoprutug demonstrated B-cell depletion and immunologic remission in pMN; additional Phase 1b data in SLE and ITP ongoing. Cash position of $227.6M funds operations into H2 2028.

    Gap Very high · 57 → Very high · 62

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 5 Nov 2026Biotech

    Climb Bio, Inc.CLYM

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 57 → Very high · 62

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.